Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00645
|
|||||
Drug Name |
Carnosine
|
|||||
Synonyms |
L-carnosine; beta-alanyl-L-histidine
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Schizophrenia [ICD11: 6A20] | Phase 2/3 | [1] | |||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C9H14N4O3
|
|||||
Canonical SMILES |
C1=C(NC=N1)CC(C(=O)O)NC(=O)CCN
|
|||||
InChI |
InChI=1S/C9H14N4O3/c10-2-1-8(14)13-7(9(15)16)3-6-4-11-5-12-6/h4-5,7H,1-3,10H2,(H,11,12)(H,13,14)(H,15,16)/t7-/m0/s1
|
|||||
InChIKey |
CQOVPNPJLQNMDC-ZETCQYMHSA-N
|
|||||
CAS Number |
CAS 305-84-0
|
|||||
Pharmaceutical Properties | Molecular Weight | 226.23 | Topological Polar Surface Area | 121 | ||
Heavy Atom Count | 16 | Rotatable Bond Count | 6 | |||
Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 5 | |||
XLogP |
-4
|
|||||
PubChem CID | ||||||
PubChem SID |
10298255
, 103529382
, 104619952
, 11113307
, 11341645
, 11361828
, 11364072
, 11366634
, 11369196
, 11372223
, 11375363
, 11377358
, 11484264
, 11487230
, 11488270
, 11491027
, 11493487
, 11494992
, 11537748
, 117531262
, 118260670
, 124558660
, 124636547
, 124883182
, 126522966
, 126608870
, 126622085
, 126623164
, 126653762
, 15121551
, 15121552
, 15196090
, 15220561
, 24893178
, 26612130
, 26679654
, 26754272
, 3138777
, 3676
, 36883477
, 47574407
, 48095570
, 49747061
, 53837760
, 74607942
, 8143363
, 85165054
, 87561884
, 88835064
, 92715522
|
|||||
ChEBI ID |
CHEBI:15727
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [2] | |
References | ||||||
1 | ClinicalTrials.gov (NCT02686697) Carnosine and Cognitive Training in Schizophrenia | |||||
2 | Transforming dietary peptides in promising lead compounds: the case of bioavailable carnosine analogs. Amino Acids. 2012 Jul;43(1):111-26. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.